What top creators are saying about Revolution Medicines, Inc.(RVMD)

The speaker said its drug could change treatment for several cancers and that the market may underestimate future revenue and earnings potential, while acknowledging the stock had already risen substantially.

Its drug could substantially change treatment for several cancers, and the market may underestimate its commercial potential, though the stock has already risen considerably.

The speaker said the stock had experienced a substantial run, using it as an example of capital rotation among biotech stocks; no company-specific outlook or recommendation was given.

Cited briefly in a discussion about how quickly a drug might move through approval, without details, endorsement, or investment outlook.

Cited as an example of good drugs receiving rapid approval, not as an AI-related investment thesis or recommendation.

Mentioned as a biotech stock that had recently risen, in contrast to Abivax and Spruce; no recommendation or company-specific thesis was provided.

The speaker suggested its drug could transform treatment for multiple cancers and that future revenue and earnings potential may be underestimated, while cautioning that the stock has already risen substantially.

Cited as a biotech stock that had experienced a strong run; no company-specific outlook or recommendation was given.

The speaker saw potential for its cancer treatment to be disruptive and said future revenue and earnings might be underestimated, while noting the stock had already risen substantially.

A roughly 9% share-price drop was noted, but no explanation or investment rationale was provided.

After RVMD fell about 9%, the team was adding a position, but the rationale and trade structure were unclear.

The speaker named Revolution Medicines among biotech companies he liked, but provided no specific thesis, catalyst, or price target.

Constructive outlook supported by oncology clinical data in pancreatic ductal adenocarcinoma, with potential interest in establishing a long position after further market sizing.

Noted for progress in KRAS-targeted therapies in pancreatic cancer, representing a potential future combination therapy candidate with next-generation mRNA cancer vaccines.

The company is making breakthroughs in 'drugging the undruggable' RAS protein, showing significant survival rate improvements in pancreatic cancer.